文献速递甲状腺疾病

补充维生素D对Graves病肌肉表现与生活质量的影响:一项随机临床试验

Effects of Supplemental Vitamin D on Muscle Performance and Quality of Life in Graves' Disease: A Randomized Clinical Trial.
PubMed 文献 · Thyroid · 2020-02-07

这项双盲随机临床试验将首次诊断Graves病且甲状腺功能亢进的患者随机分配至维生素D 70 μg(2800 IU)/天或安慰剂组,作为标准抗甲状腺药物的添加治疗。9个月维生素D补充使所有肌肉力量指标的增量减弱,在膝关节伸展60°时维生素D组较安慰剂组增量低24%(p=0.04),并显著阻碍复合生活质量改善;而抗甲状腺药物治疗与所有肌肉表现及甲状腺相关生活质量指标的显著改善相关。

要点

  • 9个月维生素D补充使膝关节伸展60°肌肉力量增量较安慰剂组低24%(p=0.04)。
  • 维生素D补充显著阻碍复合生活质量改善,总体生活质量影响和日常生活受损量表呈相同趋势。
  • 抗甲状腺药物治疗后所有肌肉力量指标增加25%至40%(p均<0.001),瘦体重增加10%(p<0.001)。

核心结论

  • 9个月维生素D补充对肌肉表现恢复产生不利影响。
  • 抗甲状腺药物治疗与所有肌肉表现及甲状腺相关生活质量指标的显著改善相关。
  • 在新诊断Graves病患者中,不推荐使用高剂量维生素D补充来改善肌肉功能,但抗甲状腺药物对缓解肌肉损伤至关重要。

研究设计与样本

  • 双盲随机临床试验,纳入首次诊断Graves病的甲状腺功能亢进患者,随机分配至维生素D 70 μg(2800 IU)/天或匹配安慰剂组,作为标准抗甲状腺药物的添加治疗。
  • 在基线以及干预3个月和9个月后评估等长肌肉力量、肌肉功能测试、姿势稳定性、体成分和使用ThyPRO问卷评估的生活质量受损。
  • 使用线性混合模型分析组间差异。
  • 试验注册号:DAGMAR研究 clinicaltrials.gov ID NCT02384668。

主要发现

  • 9个月维生素D补充导致所有研究的肌肉力量指标增量减弱,在膝关节伸展60°时维生素D组较安慰剂组增量低24%(p=0.04)。
  • 与安慰剂相比,维生素D补充倾向于减少瘦体重增加(-24%,p=0.08)。
  • 维生素D补充显著阻碍复合生活质量改善,总体生活质量影响和日常生活受损量表呈相同趋势。
  • 对抗甲状腺药物治疗的反应中,所有指标均显著改善;肌肉力量增加范围为25%至40%(p均<0.001),瘦体重增加10%(p<0.001)。
  • 所有生活质量量表均观察到大幅变化。

临床怎么用

  • 在新诊断Graves病患者中,不推荐使用高剂量维生素D补充来改善肌肉功能。
  • 抗甲状腺药物对缓解肌肉损伤至关重要。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Vitamin D deficiency has been proposed to have a role in the development and course of Graves' disease (GD). Muscle weakness and quality of life (QoL) impairments are shared features of GD and vitamin D deficiency. We aimed at investigating whether vitamin D supplementation would improve restoration of muscle performance and thyroid-related QoL in GD and at describing the effect of anti-thyroid medication (ATD) on these outcomes. Methods: In a double-blinded clinical trial, hyperthyroid patients with a first-time diagnosis of GD were randomized to vitamin D 70 μg (2800 IU)/day or matching placebo as add-on to standard ATD. At baseline and after 3 and 9 months of intervention, we assessed isometric muscle strength, muscle function tests, postural stability, body composition, and QoL-impairment by using the ThyPRO questionnaire. Linear mixed modeling was used to analyze between-group differences. (The DAGMAR study clinicaltrials.gov ID NCT02384668). Results: Nine months of vitamin D supplementation caused an attenuation of muscle strength increment in all muscle measures investigated, significant at knee extension 60° where the increase was 24% lower (p = 0.04) in the vitamin D group compared with placebo. Compared with placebo, vitamin D supplementation tended to reduce gain of lean body mass (-24%, p = 0.08). Vitamin D supplementation significantly impeded alleviation of Composite QoL and the same trend was observed for the Overall QoL-Impact and Impaired Daily Life scales. In response to ATD, all measures improved significantly. The increase in muscle strength ranged from 25% to 40% (pall < 0.001), and increment of lean body mass was 10% (p < 0.001). Large changes were observed in all QoL scales. Conclusions: Nine months of vitamin D supplementation caused unfavorable effects on restoration of muscle performance. In contrast, ATD treatment was associated with marked improvement in all measures of muscle performance and thyroid-related QoL. In patients with newly diagnosed GD, high-dose vitamin D supplementation should not be recommended to improve muscle function, but ATD is of major importance to alleviate muscle impairment.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Grove-Laugesen D, Cramon PK, Malmstroem S, et al. Effects of Supplemental Vitamin D on Muscle Performance and Quality of Life in Graves' Disease: A Randomized Clinical Trial. Thyroid. 2020. PMID: 31910101. doi:10.1089/thy.2019.0634

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。